Gland Pharma Ltd (GLAND) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 46509.56 Cr. Figures below are as reported and are shown with their source and date.
Gland Pharma Ltd. manufactures pharmaceutical ingredients and injectable formulations. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-11-20. The firm specializes in complex injectables and is engaged in the sterile injectables, oncology, and ophthalmology segments. The firm provides contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a variety of delivery systems. Its products are available in liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags, and drops. Its key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Blood Related, Cardiac, Gastrointestinal, Gynaecological, Hormones, Neuro / Cns, Ophthal / Otologicals, Pain/Analgesics, Respiratory and Vitamins / Minerals / Nutrients. Its products are sold across various countries, which include United States, Europe, Canada, and others.
Source: finedge · as of 2026-09-29
Last close (₹): 2,850.4
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 6,430.65 | 1,027.32 | 62.35 |
| Mar 2025 | 5,616.5 | 698.53 | 42.4 |
| Mar 2024 | 5,664.72 | 772.46 | 46.9 |
| Mar 2023 | 3,624.6 | 781.04 | 47.42 |
| Mar 2022 | 4,400.71 | 1,211.66 | 73.75 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Figures computed 2026-10-23.